Eli Lilly acquired AtaiBeckley, a psychedelic drug maker, because apparently the pharmaceutical industry looked at ketamine clinics and thought "we should monetize that." Big Pharma now wants to treat your depression with the same substances that made your college roommate think he could talk to trees.
The press release probably called it "expanding our neuropsychiatric portfolio." What it means is they found a way to charge your insurance $3,000 per dose for something that grows in cow sh*t.
Retail traders saw this news and immediately started scanning for penny stock psychedelic companies to buy at the top. They're currently Googling "next AtaiBeckley" while ignoring that Lilly paid for years of clinical trials, FDA relationships, and distribution networks they'll never have. But sure, that $0.47 stock with no revenue and a website built on Wix is definitely the play.
The stigma is lifting, they say. Mental health is being taken seriously. What actually happened is Lilly's actuarial team ran the numbers and realized anxious millennials with good insurance represent a better profit margin than another diabetes drug.
This is what institutional buy signals look like. Not some talking head on television. Not a analyst upgrade. A $50 billion company writing a check because their quant team determined the regulatory pathway is clear enough and the addressable market is large enough.
Your technical analysis said nothing about this. Your moving averages didn't predict it. Your Fibonacci retracements can't price in pharmaceutical M&A strategy. But you'll still check your charts tomorrow like they matter.
Lilly gets to sell regulated psychedelics to people who need them. You get to hold bags on a biotech stock that just diluted shareholders again to fund another failed Phase 2 trial.
Photo by Kanchanara on Unsplash
Leave a Comment